Skip to main content

Table 1 Baseline characteristics of the study population

From: The temporal dynamics of plasma fractalkine levels in ischemic stroke: association with clinical severity and outcome

Parameters Total stroke patients (n = 55) Favorable outcome (n = 33) Unfavorable outcome (n = 22) Control (n = 32) Pvalue
Gender      0.014
Female 25 (45%) 10 (30%) 15 (68%) 18 (56%)  
Male 30 (55%) 23 (79%) 7 (32%) 14 (44%)  
Age (Years, Median) (25th to 75th percentiles) 69 (62 to 77 ) 68 (62 to 74) 76,5 (57,75 to 85) 71 (61,25 to 75,75) 0.277
Etiology      0.258
Large artery atherosclerosis 8 (15%) 3 (9%) 5 (23%) -  
Cardioembolism 14 (25%) 7 (21%) 7 (32%) -  
Small vessel occlusion 13 (24%) 10 (30%) 3 (14%) -  
Undetermined 20 (36%) 13 (39%) 7 (32%) -  
Stroke severity      0.001
Mild 28 (51%) 23 (70%) 5 (23%) -  
Moderate/severe 27 (49%) 10 (30%) 17 (77%) -  
SBP (mmHg, Median) (25th to 75th percentiles) 135 (130 to 143) 135 (130 to 142) 135 (129 to 145,25) 130 (120 to 140) 0.453
DBP (mmHg, Median) (25th to 75th percentiles) 80 (70 to 86) 80 (70 to 88,5) 80 (70 to 85) 80 (70 to 90) 0.344
Hypertension 34 (62%) 19 (58%) 15 (68%) 24 (75%) 0.325
Nicotine consumption 10 (18%) 7 (21%) 3 (14%) 6 (19%) 0.495
Dyslipoproteinemia 19 (35%) 12 (36%) 7 (32%) 17 (53%) 0.224
Diabetes mellitus 6 (11%) 3 (9%) 3 (14%) 4 (13%) 0.853
i.v. rtPA 8 (15%) 3 (9%) 5 (23%) - 0.160
  1. Kruskal-Wallis test or Chi-square compared the groups (favorable, unfavorable strokes and controls). P<0.05 is considered significant. DBP, diastolic blood pressure; i.v. rtPA, intravenous reverse tissue-type plasminogen activator; SBP, systolic blood pressure,